The new service will help pharmaceutical industry sponsors develop flow cytrometry methodologies for use throughout the compound development lifecycle, from early trials to late-stage studies.
Tom O’Leary, president of Icon’s central labs business, explained that: “Flow Cytometry has become a preferred testing method for many of our clients, particularly those with autoimmune, oncology and immunodeficiency compounds that require more specialised testing.
“Our new Cytometry Services offering provides clients with a better range of options, all of which are supported by a team of highly experienced scientists, robust instrumentation and rigorous quality control systems